Navigation Links
Children's Hospital of Philadelphia collaborates in gene therapy success in an immune disorder
Date:11/15/2010

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

Jordan S. Orange, M.D., Ph.D., an expert in Wiskott-Aldrich syndrome (WAS), performed sophisticated cell imaging and analysis for the study, led by German researcher Christoph Klein, M.D., Ph.D., of Hannover Medical School. Orange was a senior co-author, and Children's Hospital was the only U.S. institution represented in the study, published in the Nov. 11 New England Journal of Medicine.

The proof-of-principle study marks the latest example of a recent upswing in clinical success for gene therapy. In 2009, researchers from The Children's Hospital of Philadelphia and the University of Pennsylvania reported dramatic vision improvements in patients with Leber congenital amaurosis (LCA), a form of inherited blindness. In the same year, Parisian researchers announced success in treating adrenoleukodystrophy, the disease depicted in the movie "Lorenzo's Oil." And scientists at the University of California are reporting preliminary clinical benefits in gene therapy for adenosine deaminase deficiency, an immune deficiency disorder related to "bubble boy disease."

Like WAS, all are very rare inherited disorders and have the potential to be severe and (except for LCA) life-threatening.

Wiskott-Aldrich syndrome is a complex X-linked immunodeficiency disorder characterized by recurrent infections, eczema and thrombocytopeniaa low platelet count. Mutations in the WAS gene disable its ability to produce WAS protein, which plays a crucial role in different types of immune cells. Without WAS protein, immune cells are disabled, incapable of providing immune defenses. Hence, patients are susceptible to premature death from infection, cancers or bleeding.

Although WAS has a range of severity, the only current cure is stem cell transplantation, which carries its own risks.

In the current study, based in Germany, the research team treated both children, three-year-old boys diagnosed with WAS soon after birth, by first collecting some of their hematopoietic (blood cell-forming) stem cells. They then transferred normal WAS genes into those cells and returned the cells to the boys' bloodstreams.

After treatment, the patients experienced fewer and less severe infections. Bleeding episodes decreased after platelet counts improved. Severe autoimmune anemia disappeared in one boy and severe eczema completely resolved in the other. Three years after the gene therapy, treatment-limiting adverse effects had not occurred, and the clinical benefits persisted. Significantly, the researchers reported that the treatment corrected thrombocytopenia, a hazardous and difficult-to-treat complication of WAS.

On reporting encouraging results in the first two children, the researchers noted the need to expand the study to additional patients, while conducting longer-term follow-up and analysis.

The study team found increased levels of the normal WAS protein expressed by the gene they had introduced. Orange's laboratory at Children's Hospital performed analytic imaging studies that provided evidence that the corrected immune cells were functioning normally. "Our highly quantitative imaging studies assessed natural killer cells, a critically disabled immune cell in Wiskott-Aldrich patients, and demonstrated a remarkable return to normality after gene therapy," Orange said.

Orange Translates Basic Science to Possible Immunotherapy for WAS

Orange drew on his deep background in investigating how natural killer cells function in the immune system. While a graduate student, in 1996, he discovered that natural killer cells produce cytokines, important signaling proteins, to participate in immune defense against viruses. Over the past decade he has defined the field of human natural killer cell deficiencies in various genetic disorders.

At Children's Hospital, where he treats patients, Orange is investigating a treatment for WAS distinct from gene therapy. In a current clinical trial in WAS, his immunotherapy approach bypasses the gene defect in the disease, instead using the cytokine IL-2 to boost immune function. He expects to publish initial results shortly.

"If our immunotherapy approach is safe and effective, it may represent a treatment for the full spectrum of WAS patients," he said, noting that the gene therapy trial is currently limited to the most severe cases. "Even patients with less severe WAS are at risk for lymphoma and other blood cell cancers, so broadening treatment options would be an important advance in treatment."


'/>"/>

Contact: John Ascenzi
Ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert  

Related biology news :

1. Childrens Hospital LA discovers growth factor essential to epicardial cell function
2. Brown University and Women & Infants Hospital expand national childrens study to Bristol County
3. Field-hospital-on-a-chip project awarded to nanoengineer from UC San Diego
4. First results from hospital trials testing
5. Rhode Island Hospital simulation center examines benefits and applications of medical simulation
6. Childrens Hospital scientists achieve repair of injured heart muscle in lab tests of stem cells
7. International copper industry defines role in the fight against hospital infections
8. Mount Sinai Hospital researcher makes stem cell breakthrough
9. Research could lead to new non-antibiotic drugs to counter hospital infections
10. Childrens Hospital Oakland is first pediatric hospital to use laboratory-on-a-card technology
11. Childrens Hospital Oakland scientists first to discover new source for harvesting stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Children's Hospital of Philadelphia collaborates in gene therapy success in an immune disorder
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited ... to the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... the largest German biometrics company the two government leaders could see the ... well as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:7/26/2017)... ... July 25, 2017 , ... ... manufacturing services that are necessary in the preparation and development of human cells ... facility operates under the US Food and Drug Administration’s (FDA) Current Good Manufacturing ...
(Date:7/26/2017)... ... July 26, 2017 , ... DuPont Pioneer (DuPont) ... crop productivity and economics for the food, feed and biofuel industries, announced today ... includes the research and development of microbiome-based seed treatments in corn. The goal ...
(Date:7/25/2017)... ... July 25, 2017 , ... Bactana ... improve efficiency of livestock farming while reducing the use of antibiotics and hormones ... property from Cornell University. , These new proprietary technologies expand the breadth ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... the stock market news outlet had initiated coverage on Interpace Diagnostics. Interpace ... and identifies exposure, progression and risk analysis from specific cancers in humans. ...
Breaking Biology Technology: